News

A new president may mean new rules.

Payers will have to carefully mull limited options.

Value-based health care has forced several systemic changes.

Sometimes the actual study results are less the point than the objectives of the investigators.

Enthusiasm dulled for new US biosimilar Inflectra for Rheumatoid Arthritis.

New study in a small sample of physicians implies cost factor could be a big influence.

Gaining rapid uptake for biosimilar products is a challenge for manufacturers and payers.

Pharmacokinetics of CT-P10 were highly similar to originator products.

July federal appeals court ruling will not be heard.

Supreme Court will rule on the validity of the timing.

Physicians will make their own decisions as to which patients might benefit most from biosimilars therapy.

Sandoz received a complete response letter from the US Food and Drug Administration (FDA) in regard to its pegfilgrastim biosimilar application, filed in 2015.

The prevalence of inflammatory bowel disease (IBD) among adults seems to be increasing significantly, yet there are signs that the utilization of biologics to treat patients with this chronic disease have plateaued.

As one of Shakespeare’s most famous characters asked, "What’s in a name?”, the answer in the biosimilars industry is clear: nomenclature is critical for identification purposes.

Pegylated version (pegfilgrastim) Neulasta® is the more commonly prescribed agent, with a significantly longer half-life than its predecessor and is the preferred in patients receiving cancer chemotherapy.

According to the authors of a paper published in Lancet Oncology, we may have gathered enough evidence to begin to consider altering how these agents are approved, to speed their path to approval.

A study from Norway on whether switching stable patients with rheumatoid arthritis (RA) treated with Remicade® to a biosimilar has revealed that outcomes were no different.

As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business.

Insulin glargine biosimilars supposed to contribute 15% to total cost savings in overall biologic expenditures.

Survey shows education will be needed to convince physicians of the value of biosimilar agents.

Amgen will await the outcome of its patent litigation with AbbVie before launching Amjevita.